Latest news with #BCR-ABL
Yahoo
10-06-2025
- Health
- Yahoo
Florida Cancer Specialists & Research Institute introduces liquid biopsy test
Florida Cancer Specialists & Research Institute (FCS) in the US has introduced liquid biopsy, a blood test that rapidly identifies cancerous tumours and circulating cells in the bloodstream. This test may be used to evaluate colorectal, lung, prostate, breast, and blood cancers. Liquid biopsy represents an advancement in cancer diagnosis and treatment, utilising a simple draw of blood to test for circulating tumour DNA (ctDNA). The introduction of liquid biopsy at FCS underscores the practice's focus on expanding its comprehensive genomic testing offerings, thereby improving diagnostic accuracy, guiding physicians in treatment decisions, and the patients' clinical outcomes. FCS claims to have broadened its testing options for the 250 physicians serving more than 102,000 individuals across Florida, since the introduction of next-generation sequencing (NGS) offerings at its centralised in-house laboratory in 2021. The practice has seen over 4.2 million annual visits and recently surpassed over 16,000 molecular tests processed at its Fort Myers lab facility. FCS genetics laboratory associate director Jennifer Gass said: 'Liquid biopsy is especially effective for providing genetic information quickly for various types of advanced cancers to help physicians assess and better target treatments that may work best and monitor patient response. 'Additionally, because it is minimally invasive and easy to repeat on an ongoing basis, liquid biopsy is significantly more comfortable for patients.' The expansion of the NGS testing menu at the FCS includes the addition of homologous recombination deficiency (HRD) testing, which analyses tumour DNA to determine potential treatment responses to poly (ADP-ribose) polymerase (PARP) inhibitors. This class of drugs specifically targets cancer cells. Other additions include a small heme NGS panel that identifies mutations related to myeloproliferative neoplasms and a quantitative assay for monitoring BCR-ABL gene fusions post-treatment in specific blood cancers. "Florida Cancer Specialists & Research Institute introduces liquid biopsy test" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
30-04-2025
- Business
- Yahoo
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ('Terns' or the 'Company') (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 2:30 p.m. ET. A live webcast of the fireside chat will be available on the investor relations page of the Terns Pharmaceuticals website at A replay of the webcast will be archived on Terns' website for at least 30 days following the event. About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: Contacts for Terns InvestorsKaytee Bockinvestors@ MediaJenna UrbanCG Life media@ in to access your portfolio
Yahoo
02-04-2025
- Business
- Yahoo
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ('Terns' or the 'Company') (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns. The Company granted options to purchase 611,000 shares of Terns common stock to the new employees. The options have a 10-year term and an exercise price per share equal to $2.56, which was the closing price of Terns' common stock on April 1, 2025. The options vest over four years, subject to the employees' continued service through the applicable vesting dates. About Terns Pharmaceuticals Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: Contacts for Terns InvestorsKaytee Bockinvestors@ MediaJenna UrbanCG Lifemedia@ in to access your portfolio
Yahoo
06-03-2025
- Business
- Yahoo
Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment
By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, and has been approved for certain chronic myeloid leukemia (CML) indications and included in China's National Reimbursement Drug List. Olverembatinib, is first-line treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with low-intensity chemotherapy, Ascentage said. Ph+ ALL, which accounts for 20%-30% of adult ALL cases, has poor treatment tolerance and prognosis, with existing first- and second-generation tyrosine kinase inhibitors (TKIs) facing limitations such as high relapse rates, they said. 'We are much encouraged to have olverembatinib's clinical value once again recognized by the regulatory authority in China,' Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said. 'This BTD underscores the therapeutic potential and utility of olverembatinib in Ph+ ALL, a hematologic malignancy with dismal prognosis. Moving forward, we will strive to accelerate this clinical development program for olverembatinib and bring it to more patients as quickly as possible.' Contact: Exec Edge Editor@ Sign in to access your portfolio
Yahoo
26-02-2025
- Business
- Yahoo
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ('Terns' or the 'Company') (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 24, 2025 an equity inducement award to Andrew Gengos, the Company's new chief financial officer, under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity award was approved by the Compensation Committee of the Company's Board of Directors and the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to Mr. Gengos' acceptance of employment with Terns. The Company granted Mr. Gengos a new hire option to purchase 750,000 shares of Terns common stock. The option has a 10-year term and an exercise price per share equal to $3.73, which was the closing price of Terns' common stock on February 24, 2025. The option vests over four years, subject to Mr. Gengos' continued service through the applicable vesting dates. About Terns Pharmaceuticals Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: Contacts for Terns InvestorsJustin Nginvestors@ MediaJenna UrbanCG Lifemedia@ in to access your portfolio
